Defining the role of oral pathway inhibitors as targeted therapeutics in arteriovenous malformation care

HIGHLIGHTS

• What: The relevance of this pathway was later solidified in studies focusing instead on sporadic bAVMs, which account for around 90% of all bAVMs.
• Who: Ann Mansur and Ivan Radovanovic from the Division of Neurosurgery, Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON M S , Canada have published the research: Defining the Role of Oral Pathway Inhibitors as Targeted Therapeutics in Arteriovenous Malformation Care, in the Journal: Biomedicines 2024, 1289 of /2024/
• Future: The authors place this discussion within the scope of their existing and potential targeted therapeutics for bAVM . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.